Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer-Reference-Cited by-同舟云学术

Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer

Published:2009-07 Issue:6 Volume:20 Page:519-524
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Horisberger Karoline,Erben Philipp,Muessle Benjamin,Woernle Christoph,Stroebel Philipp,Kaehler Georg,Wenz Frederik,Hochhaus Andreas,Post Stefan,Willeke Frank,Hofheinz Ralf-Dieter

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference37 articles.

1. Preoperative versus postoperative chemoradiotherapy in rectal cancer;Sauer;N Engl J Med,2004

2. Pathological features of rectal cancer after preoperative radiochemotherapy;Dworak;Int J Colorectal Dis,1997

3. Prognostic significance of tumor regression after preoperative chemoradiotherapy in rectal cancer;Rödel;J Clin Oncol,2005

4. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer;Willeke;Br J Cancer,2007

5. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer;Mehta;Int J Radiat Oncol Biol Phys,2003

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage;Biomedicine & Pharmacotherapy;2020-05

2. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice;Bulletin du Cancer;2020-04

3. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study;BMC Cancer;2019-11-29

4. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions;F1000Research;2019-09-30

5. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene;BMC Cancer;2019-06-13